These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34802050)

  • 1. Simultaneous analysis of serum α2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer.
    Hatano K; Yoneyama T; Hatakeyama S; Tomiyama E; Tsuchiya M; Nishimoto M; Yoshimura K; Miyoshi E; Uemura H; Ohyama C; Nonomura N; Fujita K
    Br J Cancer; 2022 Mar; 126(5):764-770. PubMed ID: 34802050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum core-type fucosylated prostate-specific antigen index for the detection of high-risk prostate cancer.
    Fujita K; Hatano K; Tomiyama E; Hayashi Y; Matsushita M; Tsuchiya M; Yoshikawa T; Date M; Miyoshi E; Nonomura N
    Int J Cancer; 2021 Jun; 148(12):3111-3118. PubMed ID: 33594666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
    Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer.
    Fujita K; Hayashi T; Matsuzaki K; Nakata W; Masuda M; Kawashima A; Ujike T; Nagahara A; Tsuchiya M; Kobayashi Y; Nojima S; Uemura M; Morii E; Miyoshi E; Nonomura N
    Oncotarget; 2016 Aug; 7(35):56643-56649. PubMed ID: 27494861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.
    Yoneyama T; Ohyama C; Hatakeyama S; Narita S; Habuchi T; Koie T; Mori K; Hidari KI; Yamaguchi M; Suzuki T; Tobisawa Y
    Biochem Biophys Res Commun; 2014 Jun; 448(4):390-6. PubMed ID: 24814705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 8. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.
    Chiu PK; Ng CF; Semjonow A; Zhu Y; Vincendeau S; Houlgatte A; Lazzeri M; Guazzoni G; Stephan C; Haese A; Bruijne I; Teoh JY; Leung CH; Casale P; Chiang CH; Tan LG; Chiong E; Huang CY; Wu HC; Nieboer D; Ye DW; Bangma CH; Roobol MJ
    Eur Urol; 2019 Apr; 75(4):558-561. PubMed ID: 30396635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
    Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
    Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
    BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.
    Llop E; Ferrer-Batallé M; Barrabés S; Guerrero PE; Ramírez M; Saldova R; Rudd PM; Aleixandre RN; Comet J; de Llorens R; Peracaula R
    Theranostics; 2016; 6(8):1190-204. PubMed ID: 27279911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.
    Song J; Ma S; Sokoll LJ; Eguez RV; Höti N; Zhang H; Mohr P; Dua R; Patil D; May KD; Williams S; Arnold R; Sanda MG; Chan DW; Zhang Z
    Theranostics; 2021; 11(13):6214-6224. PubMed ID: 33995654
    [No Abstract]   [Full Text] [Related]  

  • 13. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
    Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
    Barrabés S; Llop E; Ferrer-Batallé M; Ramírez M; Aleixandre RN; Perry AS; de Llorens R; Peracaula R
    Clin Chim Acta; 2017 Jul; 470():97-102. PubMed ID: 28495148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
    JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.
    Meany DL; Zhang Z; Sokoll LJ; Zhang H; Chan DW
    J Proteome Res; 2009 Feb; 8(2):613-9. PubMed ID: 19035787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer.
    Fujita K; Shimomura M; Uemura M; Nakata W; Sato M; Nagahara A; Nakai Y; Takamatsu S; Miyoshi E; Nonomura N
    Prostate; 2014 Jul; 74(10):1052-8. PubMed ID: 24802742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.